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Abstract
Background:  Genes involved in dopaminergic neurotransmission have been suggested as
candidates for involvement in smoking behavior. We hypothesized that alleles associated with
reduced dopaminergic neurotransmission would be more common in continuing smokers than
among women who quit smoking.
Methods: The study included 593 women aged 26–65 years who participated in a twelve month
smoking cessation trial conducted in 1993–1994. Participants were contacted three years after the
trial to obtain updated smoking history and biological specimens. Seven polymorphisms were
assessed in genes involved in dopamine synthesis (tyrosine hydoxylase [TH]), receptor activation
(dopamine receptors [DRD2,  DRD3,  DRD4]), reuptake (dopamine transporter [SLC6A3]), and
metabolism (catechol-o-methyltransferase [COMT]). Smoking cessation was assessed as "short-
term" quitting (abstinence for the seven days before the conclusion of the trial) and "long-term"
quitting (abstinence for the six months before a subsequent interview conducted several years
later).
Results: We observed no association of any polymorphism with either short- or long-term
quitting. Although some relative risk estimates were consistent with weak associations, either the
direction of effect was opposite of that hypothesized, or results of the short- and long-term
cessation endpoints differed. However, effect modification on smoking cessation was observed
between DRD2 Taq1A and SLC6A3 VNTR polymorphisms, DRD3 Ser/Gly and d,1-fenfluramine,
and DRD4 VNTR and d,1-fenfluramine.
Conclusion: Although these results fail to support prior findings of independent associations of
these polymorphisms with smoking status, our exploratory findings suggestive of gene-gene and
gene-treatment interactions warrants further investigation.
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Background
Nicotine is the primary addictive component of tobacco,
and its addictive effects operate through dopamine neuro-
transmission in the brain's mesolimbic "reward" path-
way. Genes that code for constituents of the dopaminergic
system are considered candidates for involvement in
addictive behaviors, including smoking. Within a cohort
of women who participated in a randomized smoking ces-
sation trial, we examined the relation of polymorphisms
in genes related to dopamine synthesis (tyrosine hydroxy-
lase [TH]), receptor activation (DRD2,  DRD3,  DRD4),
transport and synaptic reuptake (the dopamine trans-
porter [SLC6A3]) and metabolism (catechol-O-methyl-
transferase [COMT]) with the ability to quit smoking.
The genes and polymorphisms were selected based on
prior reports of an association with smoking behavior as
well as reports of associations with other addictive behav-
iors such as alcoholism. We hypothesized that alleles
associated with reduced dopaminergic neurotransmission
(whether due to decreased dopamine production,
increased metabolism, increased synaptic reuptake, or
reduced receptor activation) would be less common
among women who quit smoking than among continu-
ing smokers. The DRD2 receptor gene, for example, is pol-
ymorphic in the promoter region where the gene can exist
as an insertion or deletion variant at position -141
(rs1799732). Because the deletion variant is associated
with lower promoter activity [1], we expected that the pol-
ymorphic form would presumably decrease dopamine
neurotransmission and would be associated with a
decreased ability to quit smoking. Similarly, downstream
on the same DRD2 receptor gene exists a polymorphism
identified by the Taq1A restriction enzyme (A1 allele)
(rs1800497), which is associated with reduced receptor
binding [2,3]. Because of this reduced receptor binding
ability, we hypothesized that the A1 allele would also be
associated with a decreased ability to quit smoking. In
contrast, the single nucleotide substitution of G by A in
codon 158 of the COMT gene resulting in an amino acid
change from valine to methonine (rs4680) is associated
with low enzyme activity and thermolability [4]. We
hypothesized that a reduced ability of this COMT poly-
morphic enzyme to metabolize dopamine would presum-
ably increase dopamine neurotransmission and be
associated with a higher likelihood of quitting smoking.
We also selected other polymorphisms that have been
associated with smoking or addictive behaviors in prior
reports, and based our hypothesis of their affect on smok-
ing cessation from existing literature. These include DRD3
Ser9Gly (rs6280) DRD4 variable number tandem repeat
(VNTR) in third exon, SLC6A3 VNTR in 3' untranslated
region, and TH VNTR in first intron. Table 1 summarizes
the genes and polymorphisms we assessed, the possible
effect of the variant allele on dopaminergic neurotrans-
mission, and the hypothesized direction of effect on
smoking cessation. Because results of prior studies of the
relation between these selected polymorphisms and
smoking behavior have been inconsistent, our assessment
of these polymorphisms in a population of female smok-
ers who were highly motivated to quit could contribute to
a greater understanding of genetic influences on smoking
cessation.
Methods
Study population
Eligible individuals were female residents of Washington
State who had participated in a double-blinded rand-
omized controlled trial conducted at the Fred Hutchinson
Cancer Research Center (FHCRC) in Seattle, Washington
in 1993 and 1994, investigating a pharmacologic agent,
d,l-fenfluramine, as a component of smoking cessation
treatment [5]. The 723 participants were between 26 and
65 years of age, weighed within 85–150 percent of ideal
weight for height based on the Metropolitan Life Tables,
and smoked more than 10 cigarettes per day at randomi-
zation. At entry into the trial, each woman completed
questionnaires regarding: smoking behavior; other behav-
iors, including patterns of food and alcohol consumption;
smoking-related beliefs; confidence in quitting; and a
variety of psychological measures. All women received a
self-help smoking cessation program from the American
Lung Association. Women were randomized to receive
either d,1-fenfluramine or placebo control in a double-
blinded fashion. Quit outcome was assessed at 12-month
follow-up.
For the current genetic study, we contacted clinical trial
participants to request a biological specimen (blood or
buccal cells) and to re-assess smoking behavior several
years after completion of the trial (median, 3.3 years).
Data and specimens were obtained from 593 women, 517
of whom provided blood and 76, buccal cells. DNA
extraction and genotyping were conducted at the Func-
tional Genomics Laboratory of the Center for Ecogenetics
and Environmental Health at the University of Washing-
ton. The following polymorphisms were assessed: COMT
Val158Met (rs4680), DRD2 -141C Ins/Del (rs1799732),
DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280), and
VNTRs in the DRD4, SLC6A3, and TH genes. Laboratory
personnel were blinded to smoking status and quality
control samples were used to ensure accurate genotyping
techniques. Primers, probes and conditions for genotyp-
ing assays are available upon request. All study activities
received human subjects approval by the Fred Hutchinson
Cancer Research Center Institutional Review Board.Behavioral and Brain Functions 2007, 3:22 http://www.behavioralandbrainfunctions.com/content/3/1/22
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Outcome measurement
We assessed smoking status at two points in time. First,
women were considered "short-term" quitters if they had
not smoked for at least the seven day period before their
12-month follow-up in the original clinical trial. Second,
we defined "long-term" quitters as those who reported
smoking abstinence for at least six consecutive months
immediately before their 3-year interview for the current
study. We analyzed plasma samples from self-reported
long-term quitters for cotinine to validate reported smok-
ing status. Women initially categorized as long-term quit-
ters who had a cotinine level of 14 nanograms per
milliliter or greater [6] and who did not report recent use
of nicotine gum and/or patch (n = 4) were re-categorized
as continuing smokers.
Statistical analysis
For VNTR polymorphisms, we categorized alleles based
on number of repeats according to groupings used in prior
studies. For DRD4, the alleles containing 2–5 repeats were
considered short and alleles containing 6–10 repeats were
considered long. For SLC6A3, alleles were categorized
based on the presence or absence of a 9-repeat. For TH,
alleles were categorized based on the presence or absence
of a 10-repeat. With the exception of the COMT
Val158Met polymorphism, for which there were a suffi-
cient number of individuals in the homozygous variant
(Met/Met) category to consider separately, we grouped
individuals who were heterozygous with those who were
homozygous variants for analysis. We computed relative
risks (RR) of short-term and long-term smoking cessation
using the Mantel-Haenszel estimator to compute crude
and adjusted RRs. Ninety-five percent confidence intervals
(CI) were calculated for all RR estimates. Analyses were
conducted for the entire study population and also after
restricting to non-Hispanic Whites. We assessed potential
confounding by age, race, and intervention arm of the
randomized trial, and conducted analyses separately
among younger and older women. Because prior studies
reported an effect modification between SLC6A3  and
DRD2 Taq1A polymorphisms on smoking cessation, we
examined the influence of the combination of these two
polymorphisms on smoking cessation in our population.
We also explored whether any of the polymorphisms of
interest modified the effect of treatment intervention on
smoking cessation in this population. Data management
and statistical analyses were conducted using STATA Ver-
sion 8 (StataCorp, College Station, TX, USA) and SAS soft-
ware Version 6.12 (SAS Institute Inc., Cary, NC, USA).
Results
Participants (n = 593) and non-participants (n = 130) did
not differ on demographics, intervention arm, baseline
smoking and drinking characteristics, or short-term quit
status (21 percent and 19 percent, respectively, were con-
sidered quitters; p = 0.7). Long-term quit status was only
assessed in those who participated in the long-term inter-
view (median, 3.3 years after enrollment in clinical trial).
The proportion of women randomized to d,l-fenflu-
ramine was similar between those who did and did not
quit smoking for both cessation outcomes. The majority
of participants (93%) were non-Hispanic Caucasian.
Compared to women who continued to smoke at either
time point, those who were short- or long-term quitters
had higher income and educational levels, consumed less
alcohol, started smoking at a later age, smoked fewer
Table 1: Summary of candidate genes, polymorphisms, and their presumed effect on smoking cessation under the hypothesis that 
reduced dopaminergic neurotransmission is associated with lower likelihood to quit smoking.
Gene Function of Gene Product Polymorphism (Allele of 
interest)
Reported effects or associations 
of variant [reference]
Presumed effect on 
dopamine neuro-
transmission
Expected direction of effect on 
smoking cessation among those 
with variant allele
COMT Dopamine metabolism Val158Met (Met) Met associated with low enzyme 
activity and thermolability [4]
Increase more likely to quit smoking
DRD2 Dopamine receptor -141C Ins/Del in promoter 
region (Del allele)
Lower promoter activity [1] Decrease less likely to quit smoking
DRD2 Dopamine receptor Taq1 A at 10 kb downstream 
of coding sequence (A1 allele)
Reduced receptor binding [2, 3] Decrease less likely to quit smoking
DRD3 Dopamine receptor Ser9Gly in N, terminal 
extracellular domain (Gly 
allele)
High dopamine binding affinity in 
Gly9 homozygotes [40]
Increase more likely to quit smoking
DRD4 Dopamine receptor (long repeat alleles: 6, 10 
repeats)
7-repeat alleles have decreased 
intracellular response to 
dopamine [41]
Decrease less likely to quit smoking
SLC6A3 Dopamine reuptake VNTR in 3' untranslated 
region (9-repeat allele)
9-repeat alleles associated with 
lower levels of dopamine 
transporter expression [42] and 
lower brain protein levels [43]
Increase more likely to quit smoking
TH Dopamine synthesis TCAT, tetranucleotide VNTR 
first intron (10-repeat allele)
10-repeat allele associated with 
reduced HVA levels (measure of 
dopamine metabolism) [44]
Decrease less likely to quit smokingBehavioral and Brain Functions 2007, 3:22 http://www.behavioralandbrainfunctions.com/content/3/1/22
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numbers of cigarettes per day, and had smoked for a
shorter period of time when assessed at enrollment in the
trial (Table 2).
Information on short-term quit was available for 563
women, 116 (21%) of whom were categorized as non-
smokers and 447 (79%) as smokers at this time point. For
long-term cessation outcome, 93 (16%) women had quit,
and 500 (84%) continued to smoke. Fifty-nine of 116
women (51%) were non-smoking at both time points.
Those who had quit for the short-term were 6.9 times
Table 2: Characteristics of 593 women by short-term and long-term smoking cessation status, Seattle, WA, 1993–1998.
Short-term Smoking Cessation Long-term Smoking Cessation
Quit (n = 116) Did not quit (n = 447) Quit (n = 93) Did not quit (n = 500)
Characteristic* N % N % N % N %
Race/Ethnicity
Caucasian American 109 94.0 413 92.4 92 98.9 458 91.6
African American 3 2.6 17 3.8 0 0.0 20 4.0
Asian Pacific Islander 0 0.0 5 1.1 0 0.0 5 1.0
Hispanic & Latin American 1 0.8 0 0.0 0 0.0 2 0.2
American Indian & Native Alaskan 0 0.0 3 0.7 0 0.0 3 0.6
Other 3 2.6 9 2.0 1 1.1 12 2.4
Age (years)
<40 42 36.2 161 36.0 35 37.6 181 36.2
40–49 47 40.5 175 39.1 40 43.0 195 39.0
50–59 24 20.7 95 21.2 17 18.2 106 21.2
≥60 3 2.6 16 3.6 1 1.1 18 3.6
Educational level (years)
<12 4 3.5 13 2.9 2 2.2 18 3.8
= 12 34 20.1 143 33.6 25 27.8 160 33.5
>12 75 66.4 270 63.4 63 70.0 299 62.7
Refused 3 21 3 23
Employed
Yes 82 70.7 338 75.8 69 74.2 371 74.2
Missing 0 1
Annual income
≤ $25,000 22 19.1 99 22.6 14 15.1 120 24.5
$26,000–50,000 58 50.4 225 51.4 46 49.5 247 50.5
> $50,000 35 30.4 114 26.0 33 35.4 122 25.0
Refused 0 4 0 4
Missing 1 5 0 7
Alcohol use 1 month prior to trial
None 40 37.0 128 33.9 35 42.2 137 33.1
1–10 Drinks 51 47.2 163 43.1 32 38.6 187 45.2
11–19 Drinks 5 4.6 32 8.5 5 6.0 33 8.0
≥ 20 Drinks 12 11.1 55 14.6 11 13.3 57 13.8
Missing 8 69 10 86
Average cigarette use
10–19 cigarettes/day 33 29.2 92 20.9 25 27.5 106 22.2
20–39 cigarettes/day 69 61.1 309 70.2 58 63.7 338 68.7
40–59 cigarettes/day 10 8.8 32 7.3 7 7.7 40 8.1
≥60 cigarettes/day 1 0.9 7 1.6 1 1.1 8 1.6
Missing 3 7 2 8
Age started smoking
≤13 6 5.2 49 11.0 4 4.3 57 11.4
14–18 66 56.9 287 64.3 52 56.5 319 63.8
19–22 32 27.6 83 18.6 30 32.6 89 17.8
≥23 12 10.3 27 6.1 6 6.5 35 7.0
Missing 0 1 1 0
Total duration of smoking up to entry into trial
≤9 years 4 3.4 1 1 1.1 4 0.8
10–19 years 26 22.4 93 26 28.3 100 20.0
20–29 years 54 46.7 192 38 41.3 222 44.4
30–39 years 27 23.3 129 25 27.1 140 28.0
≥40 years 5 4.3 31 2 2.2 34 6.8
Missing 0 1 1 0
Trial intervention arm
Fenfluramine 56 48.3 226 51 54.8 240 48.0
*At entry into clinical trial, unless otherwise indicatedBehavioral and Brain Functions 2007, 3:22 http://www.behavioralandbrainfunctions.com/content/3/1/22
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(95% CI: 4.7, 10.0) more likely to be non-smoking at the
later time point.
Distributions of genotypes for all the polymorphisms did
not deviate to any appreciable extent from expectation
predicted by Hardy-Weinberg equilibrium. We observed
no association between any of the individual polymor-
phisms examined and smoking cessation either for the
short- or long-term quit outcomes (Table 3). Although, in
a few instances, RR estimates appeared to be suggestive of
a weak association with smoking (albeit with wide confi-
dence intervals), either the direction of effect was in the
opposite of that hypothesized or results of the short-term
and long-term cessation endpoints were inconsistent. For
example, while we observed a decreased likelihood of
quitting in the short-term (RR = 0.9; 95 percent CI: 0.6,
1.5) and long-term (RR = 0.7; 95% CI: 0.4, 1.3) among
women with two copies of the COMT Met allele, we had
hypothesized that the lower activity Met allele would
occur more commonly among women who quit smoking.
While a 30% increase in likelihood of quitting in the
short-term was observed among women with one or more
9-repeat alleles of the SLC6A3 gene (RR = 1.3; 95% CI: 0.9,
1.8), no association with long-term quitting was observed
(RR = 1.1; 95% CI: 0.7, 1.6).
Adjustment for race, age, or intervention arm of the rand-
omized trial had no appreciable influence on the risk esti-
mates. Analyses restricted to non-Hispanic Caucasian
women yielded similar results, as did analyses conducted
separately among younger (<50 years) and older (≤ 50
years) women. We also conducted analyses in which we
compared women who were categorized as both short-
term and long-term quitters to women who had not quit
smoking at either of these two time points; again, we
observed no relation of any of the polymorphisms
assessed with the likelihood of quitting smoking. We fur-
ther observed no association of any set of combinations of
dopamine receptor polymorphisms with smoking cessa-
tion for either outcome (data not shown).
There was no relation between having a SLC6A3 9-repeat
allele and short-term (RR: 0.9; 95% CI: 0.6, 1.4) or long-
term (RR: 0.8; 95% CI: 0.5, 1.4) quitting among women
with the more common A2/A2 genotype for DRD2 Taq1A.
However, women with one or two copies of the SLC6A3
9-repeat allele who also had either the DRD2 Taq1A A1/
A1 or A1/A2 genotypes were significantly more likely to
quit in both the short- (RR = 2.5; 95% CI: 1.3, 4.7) and
long-term (RR = 1.8; 95% CI: 0.9, 3.6). We also assessed
the moderating effects of genotype on the pharmacologic
Table 3: Relation of gene polymorphisms with short-term and long-term smoking cessation among 593 women, Seattle, WA, 1993–
1998.
Short-term smoking cessation Long-term smoking cessation
Quit Did not quit Quit Did not quit
Polymorphism N % N % RR 95% CI N % N % RR 95% CI
COMT Val158Met
Val/Val 25 22 112 25 1.0 Ref 24 26 120 24 1.0 Ref
Val/Met 63 56 204 46 1.3 0.9, 2.0 49 53 234 48 1.0 0.7, 1.6
Met/Met 25 22 124 28 0.9 0.6, 1.5 19 21 136 28 0.7 0.4, 1.3
DRD2 Taq1A
A2/A2 77 67 283 64 1.0 Ref 62 67 316 64 1.0 Ref
A2/A1; A1/A1 38 33 160 36 0.9 0.6, 1.3 31 33 177 36 0.9 0.6, 1.4
DRD2 -141C Ins/Del
Ins/Ins 91 79 337 76 1.0 Ref 75 80 378 76 1.0
Ins/Del; Del/Del 24 21 106 24 0.9 0.6, 1.3 18 20 117 24 0.8 0.5, 1.3
DRD3 Ser9Gly
Ser/Ser 53 46 188 42 1.0 Ref 45 48 211 43 1.0 Ref
Ser/Gly; Gly/Gly 62 54 256 58 0.9 0.5, 1.2 48 52 284 57 0.8 0.6, 1.2
DRD4 VNTR
Short/Short 71 63 256 59 1.0 Ref 53 58 290 60 1.0 Ref
Short/Long; Long/Long 42 37 179 41 0.9 0.6, 1.2 39 42 193 40 1.1 0.7, 1.6
SLC6A3 VNTR
No 9 repeats 57 51 259 59 1.0 Ref 50 55 283 58 1.0
One or two 9 repeats 55 49 183 41 1.3 0.9, 1.8 41 44 209 42 1.1 0.7, 1.6
TH VNTR
No 10 repeats 50 43 207 46 1.0 Ref 39 42 235 47 1.0 Ref
One or two 10 repeats 66 57 240 54 1.1 0.8, 1.5 54 59 265 53 1.2 0.8, 1.7Behavioral and Brain Functions 2007, 3:22 http://www.behavioralandbrainfunctions.com/content/3/1/22
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agent, d,l-fenfluramine, offered in the clinical trial in
which these women previously participated. Except for
DRD3 Ser9Gly and DRD4 VNTR polymorphisms, d,1-fen-
fluramine did not appear to have an effect on smoking
cessation in any subgroup for any of the polymorphisms
we assessed (data not shown). The likelihood of quitting
smoking associated with the use of d,1-fenfluramine was
slightly increased for those who carried at least one Gly
allele in the DRD3 gene (RR = 1.5; 95% CI: 0.9, 2.6), but
not for those homozygous for the Ser allele (RR = 1.05;
95% CI:, 0.62, 1.78). Among those with two short-repeat
alleles in the DRD4 VNTR, d,1-fenfluramine was signifi-
cantly associated with a higher chance of quitting (RR =
1.8; 95% CI: 1.0, 3.9). Women with one or two long-
repeat alleles, however, did not benefit from the interven-
tion (RR = 0.8; 95% CI 0.4–1.4). Table 4 summarizes our
findings regarding these modifying effects.
Discussion
Our study has several strengths. Relative to cross-sectional
studies that assess smoking status at a single time point,
the cohort design of this study allowed us to focus on ces-
sation independent of other aspects of smoking behavior
(such as initiation) and to assess quitting behavior at two
widely separated time points. Examining genetic influ-
ences within a group of moderate to heavy smokers who
were sufficiently motivated to quit that they chose to par-
ticipate in a randomized trial might be expected to
enhance our ability to isolate and identify genetic effects
on smoking cessation (independent of psychosocial fac-
tors related to motivation), relative to studies based on
comparisons of smokers and nonsmokers. The conduct of
this study within a female population, coupled with the
lack of effect of the d,l-fenfluramine intervention on
smoking cessation [7], minimizes the extent to which our
results might be influenced by gender or treatment arm.
Nevertheless, the study is vulnerable to several potential
sources of error and issues of generalizability. Some mis-
classification of smoking status might be expected, since
determination of short-term quitting was based entirely
on self-report. Long-term quitting was verified with
plasma cotinine levels. However, because cotinine levels
of a typical habitual smoker (200 ng/ml) [8] decline to
nonsmoking values by the third day of abstinence (based
on the average half-life of 16–19 hours) [9], individuals
Table 4: Gene-gene and gene-treatment interaction for smoking cessation in 593 women, Seattle, WA, 1993–1998.
Short-term Quit Long-term Quit
Quit Did not quit Quit Did not quit
N% N % R R9 5 %  C I N% N % R R9 5 %  C I
DRD2 Taq1 A2/A2
SLC6A3
no 9-repeats 45 60.0 164 58.2 1.0 Ref 38 62.3 181 57.6 1.0 Ref
one or two 9-repeats 39 40.0 118 41.8 0.9 0.6, 1.4 23 37.7 133 43.4 0.8 0.5, 1.4
DRD2 Taq1 A1/A2 or A1/A1
SLC6A3
no 9-repeats 12 32.4 95 58.8 1.0 Ref 12 40.0 101 57.4 1.0 Ref
one or two 9-repeats 25 67.6 64 40.2 2.5 1.3, 4.7 18 60.0 75 42.6 1.8 0.9, 3.6
DRD3 Ser/Ser
Arm
Placebo 26 49.1 96 51.1 1.0 Ref 23 51.1 111 52.6 1.0 Ref
D,1-fenfluramine 27 50.9 92 48.9 1.1 0.7, 1.7 22 48.9 100 47.4 1.1 0.6, 1.8
DRD3 Ser/Gly and Gly/Gly
Arm
Placebo 33 53.2 124 48.4 1.0 Ref 19 39.6 146 51.4 1.0 Ref
D,1-fenfluramine 29 46.8 132 51.6 0.9 0.5, 1.3 29 60.4 138 48.6 1.5 0.9, 2.6
DRD4 short/short
Arm
Placebo 32 45.1 118 46.1 1.0 Ref 18 34.0 145 50.0 1.0 Ref
D,1-fenfluramine 39 54.9 138 53.9 1.0 0.7, 1.6 35 66.0 145 50.0 1.8 1.0, 3.0
DRD4 short/long and long/long
Arm
Placebo 26 61.9 97 54.2 1.0 Ref 24 61.5 106 54.9 1.0 Ref
D,1-fenfluramine 16 38.1 82 45.8 0.8 0.4, 1.4 15 38.5 87 45.1 0.8 0.4, 1.4Behavioral and Brain Functions 2007, 3:22 http://www.behavioralandbrainfunctions.com/content/3/1/22
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who had smoked at some point within the six month time
period used to define this endpoint may still be misclassi-
fied. Furthermore, our results may not be generalizable to
populations that were either excluded or not well-repre-
sented in our study such as men, women who are not
within 85–150% of ideal body weight, and non-white
racial or ethnic populations.
Clear and consistent findings have not emerged in
research examining candidate gene polymorphisms in
relation to smoking behavior. Results of studies of the
relation between the COMT  Val158Met polymorphism
and smoking behavior have been inconsistent [10-12].
Several studies that have examined the relation of this pol-
ymorphism with smoking cessation or nicotine depend-
ence among smokers participating in cessation trials
reported positive findings. Collila and colleagues
observed that women recruited from a smoking cessation
trial who had the Met/Met genotype were more likely to
have abstained from smoking for at least seven days (OR
= 2.96; 95% CI: 1.07, 8.14) and for a prolonged period of
time (OR = 3.23; 95% CI: 1.13, 9.20) [10]. In another
report, investigators observed a positive relation between
nicotine dependence and the presence of the high activity
(Val) allele of COMT (p = 0.0072) in a population of male
and female smokers enrolled in cessation trials; however,
they were unable to replicate these findings in an inde-
pendent group of trial participants [13].
Observational studies assessing the DRD2  Taq1A poly-
morphism and smoking characteristics have also had
inconsistent findings. Whereas the results of some studies
suggest an association between the A1 genotype and cur-
rent or past smokers relative to nonsmokers, [14-17].
Studies of subjects recruited from clinical trials have also
reported associations of smoking behavior with the DRD2
Taq1A polymorphism in non-Hispanic Caucasian popu-
lations. In a study of 134 male and female smokers from
a trial of venlafaxine or placebo plus standard of care (e.g.,
counseling and nicotine patch), those with the A2/A2 gen-
otype were more likely to quit smoking than smokers with
at least one A1 allele [18]. In contrast, among enrollees of
a clinical trial of buproprion plus counseling, women
with at least one DRD2 Taq1 A1 allele were somewhat less
likely to report smoking at 12-month follow-up compared
to women who carried two A2 alleles (OR = 0.76; 95% CI:
0.56, 1.03); no such association was observed among men
[19]. In a study of 600 male and female smokers enrolled
in a clinical trial of befloxatone or placebo plus coun-
seling, individuals with genotypes containing the A1
allele were less likely to sustain abstinence during the last
four weeks of the treatment period (OR = 0.74; 95% CI:
0.46, 1.18) [20]. Overall, a meta-analysis of 12 studies of
DRD2  Taq1A polymorphisms found no association
between this polymorphism and smoking cessation (OR
= 1.17; 95% CI: 0.89, 1.55) [21].
Opposite directions of associations with the DRD2 Taq1A
polymorphism have been observed in some studies of
ethnic populations. In a study of lung cancer, the A1/A1
genotype was associated with current smoking status
among Mexican-American but not in African-American
control subjects [22]. Among 332 Japanese individuals
recruited from an outpatient clinic of Aichi Cancer Center,
those with the A2/A2 genotype displayed a greater likeli-
hood of having ever smoked (OR = 3.68; 95% CI: 1.50,
9.05) or were more likely to be current smokers (OR =
3.72; 95% CI: 1.23, 11.2) relative to those with the A1/A1
genotype after adjusting for sex and age [23]. Another
study of Japanese individuals recruited from the same
clinic partially replicated this finding. Compared to men
with the A1/A1 genotype, men with the A2/A2 genotype
were more likely to be current smokers (OR = 2.32; 95
percent CI: 1.02, 5.29). This association, however, was not
apparent in women [24]. In a population of Chinese
smokers, those with the A2/A2 genotype smoked a greater
number of cigarettes per day than smokers with at least
one A1 allele [25]. Among 187 healthy Koreans geno-
typed for the DRD2 Taq1A polymorphism, men carrying
the A1 allele were more commonly smokers (p = 0.049)
whereas women with the A1 allele were more likely to be
nonsmokers (p = 0.018), with no association observed
when men and women were pooled together [26].
Results of studies on the SLC6A3 VNTR, TH VNTR, DRD2
-141C Ins/Del and DRD3  Ser9Gly polymorphisms are
either lacking or conflicting. SLC6A3 9-repeat genotypes
were observed to correlate with non-smoking status,
smoking cessation, later age of smoking initiation, and
long periods of quitting in early studies [27,28], but these
associations were not observed in subsequent studies
[29,30]. In a meta-analysis of four studies, the SLC6A3
VNTR polymorphism was not associated with smoking
cessation in a fixed-effects model (OR = 0.85; 95% CI:
0.68, 1.08) or random-effects model (OR = 0.89; 95% CI:
0.63, 1.28) [21]. An examination of the TH VNTR poly-
morphism found no association with the likelihood of
smoking in either Caucasians or African-Americans.
Among smokers, however, the TH1 allele (the longest pol-
ymorphic repeat, corresponding to the 10-repeat allele in
our study) was associated with a higher smoking rate and
the TH4 allele (corresponding to the 7-repeat allele) was
associated with a lower smoking rate [31]. The TH4 allele
was also observed to be inversely associated with nicotine
dependence among adolescent smokers in two independ-
ent populations in Australia [32,33]. The DRD2 -141C
Ins/Del polymorphism was examined in one study
among a Japanese population, but was not associated
with smoking status [23]. DRD3 Ser9Gly has not beenBehavioral and Brain Functions 2007, 3:22 http://www.behavioralandbrainfunctions.com/content/3/1/22
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previously examined in relation to smoking behaviors,
although it has been assessed, with inconsistent results, in
studies of other addictive behaviors.
Variations in the definition or timing of smoking assess-
ment may explain, in part, some of the dissimilar results
between studies. For example, Vandenberg and colleagues
observed differences in the relation of smoking with the
SLC6A3 9-repeat allele when smokers were compared to
"never smokers" (i.e., individuals who had never smoked
a cigarette) versus "nonsmokers" (i.e., those who had ever
smoked less than 100 cigarettes) [30], suggesting that
important information may be gained by distinguishing
between those who have never smoked and those who
have smoked less than 100 cigarettes. Furthermore, smok-
ing cessation is a dynamic process characterized by high
rates of relapse, possibly influencing the power to detect
effects at different time periods. In several smoking cessa-
tion trials, the effect of time on weekly abstinence rates
was appreciable: abstinence rates rose through the first
several weeks and declined over time [18,20]. Even
among individuals who abstain from smoking for seven
months, relapse rates between 7% and 35% have been
reported [34].
Gender appears to be related to smoking cessation in
complex ways. Men have been reported to have lower
rates of relapse relative to women [35], and smoking ces-
sation may be more difficult for women for reasons per-
taining to demographic and smoking history [36], weight
control, or social support [37]. As described above, several
studies have reported gender differences in the relation of
the DRD2 Taq1 polymorphism with smoking behavior.
Other studies have observed gene-gene interactions with
smoking status or cessation. Lerman and colleagues
reported an interaction of the DRD2 Taq1A and SLC6A3
VNTR polymorphisms in a population of 289 smokers
and 233 controls in which non-Hispanic Caucasian par-
ticipants with SLC6A3  9-repeat genotypes were more
likely to be nonsmokers relative to those without a 9-
repeat allele among those with the DRD2 Taq1 A2/A2
genotype (p = 0.008). Among those with the DRD2 Taq1
A1 genotypes, the SLC6A3  9-repeat was not associated
with smoking status (p = 0.51) [28]. These investigators
also observed a gene-gene interaction between the same
two polymorphisms and smoking cessation in a popula-
tion of 418 smokers of European Caucasian descent
enrolled in a clinical trial of bupropion [38]. In contrast
to these findings, we observed an increased likelihood of
smoking cessation among a different group defined by
DRD2  Taq1A and SLC6A3  9-repeat genotypes: women
with the SLC6A3  9-repeat genotypes had an increased
likelihood of quitting in either the short-term or long-
term, relative to women without a SLC6A3 9-repeat allele,
only if they also possessed the DRD2 Taq1 A1 genotypes.
There was no apparent association between the SLC6A3 9-
repeat genotypes and smoking cessation for either time
point among women with the DRD2 Taq1 A2/A2 geno-
type. The discrepancies of these various studies are not
readily explainable by differences in the distribution of
racial, ethnic or gender characteristics of the study popu-
lations.
In our exploration of whether d,1-fenfluramine may be
more effective in certain subgroups defined by genotypes,
we observed an increased likelihood of quitting smoking
associated with d,1-fenfluramine among those with one
or two DRD3 glycine alleles in the long-term (RR = 1.5;
95% CI: 0.9, 2.6), but not among smokers without the
glycine allele (RR = 1.1; 95% CI: 0.6 1.8). For women with
two short alleles in the DRD4 VNTR polymorphism, d,1-
fenfluramine appeared more effective in helping them
quit smoking than for women with one or two long alle-
les. Studies examining the influence of genotypes on d,1-
fenfluramine's effectiveness in smoking cessation are not
available, although a recent study has identified a more
favorable outcome for bupropion treatment among Euro-
pean-American smokers with the COMT  haplotypes
(rs737865 and rs165599) [39]. Similar studies may be
important in identifying likely responders for common
smoking cessation treatments.
Conclusion
Our results, together with the inconsistent findings of
prior studies, provide little support for an independent
relation of the candidate polymorphisms we assessed with
smoking cessation. However, a substantial literature
based on twin studies suggests that aspects of smoking
behavior are highly heritable. Findings from our explora-
tion of effect modification suggest possible important
gene-gene and gene-treatment interactions for smoking
cessation. Future studies examining genetic influences on
smoking cessation may prove more informative if they are
designed to completely characterize variation in the genes
of interest, or to more effectively identify subgroups of
smokers who are more genetically inclined to quit smok-
ing or for whom certain pharmacologic interventions may
be more efficacious.
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